

Brilliant Violet 605™ anti-human CD184 (CXCR4)

Catalog # / Size: 2132610 / 100 tests
2132605 / 25 tests

Clone: 12G5

Isotype: Mouse IgG2a, κ

Immunogen: CP-MAC-infected Sup-T1 cells


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Workshop Number: VII 70204

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD184 (clone 12G5) Brilliant Violet 605™ (filled histogram) or mouse IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of paraffin-embedded tissue sections¹¹, immunocytochemistry³, immunofluorescence microscopy^{2,6}, and blocking of CD4-independent infection by HIV-2 and CD4-dependent infection by some T cell-tropic isolates of HIV-1^{4,5}. Clone 12G5 may not be suitable for Western blotting.¹⁰ The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 306512).

- Application** 1. McKnight A, *et al.* 1997. *J. Virol.* 71:1692.
- References:** 2. Endres MJ, *et al.* 1996. *Cell* 87:745. (Immunogen, IF)
3. Volin MV, *et al.* 1998. *Biochem. Biophys. Res. Commun.* 242:46. (ICC)
4. Berndt C, *et al.* 1998. *P. Natl. Acad. Sci. USA* 95:12556. (Block)
5. Ullrich CK, *et al.* 2000. *Blood* 96:1438. (Block)
6. Murga M, *et al.* 2005. *Blood* 105:1992. (IF)
7. Thompson BD. 2007. *J. Biol. Chem.* 282:9547. (FC) [PubMed](#)
8. Isnardi I, *et al.* 2010. *Blood* 115:5026. [PubMed](#)
9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
10. Fischer T, *et al.* 2008. *PLoS One* 3:e4069.
11. Schmid BC, *et al.* 2004. *Breast Cancer Res. Treat.* 84:247. (IHC)
-

Description: CD184, also known as fusin or CXCR4, is a 45 kD seven transmembrane G-protein-linked CXC chemokine receptor. CD184 is widely expressed on blood and tissue cells, including B and T cells, monocytes, macrophages, dendritic cells, granulocytes, megakaryocytes/platelets, lymphoid, myeloid precursor cells, endothelial cells, epithelial cells, astrocytes, and neurons, among other tissue cells. CD184 is the receptor for CXC chemokine SDF-1, mediates blood cell migration, and is involved in B lymphopoiesis and myelopoiesis, cardiogenesis, blood vessel formation, and cerebellar development. CXCR4 is also a coreceptor of X4 HIV-1 and an alternative receptor for some isolates of HIV-2.

- Antigen** 1. Berger E, *et al.* 1999. *Annu. Rev. Immunol.* 17:657.
- References:** 2. Loetscher P, *et al.* 2000. *Adv. Immunol.* 74:127.
3. Murphy P, *et al.* 2000. *Pharmacol. Rev.* 52:145.